Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 384

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 384
---
 to develop products
using the Group’s nanomedicine and sustained release technology platforms. All the reconciliations required for segmental reporting
can be found in the primary statements.

The accounting policies
of the reportable segments are consistent with the Group’s accounting policies described in note 1.

| F-42 |

| 4 | Loss from operations |

| Schedule of loss from operations                                                               |     |      |     |            |     |            |     |            |   |
|                                                                                                |     | Note |     | 2023 £’000 |     | 2022 £’000 |     | 2021 £’000 |   |
| Loss from operations is stated after charging/(crediting):                                     |     |      |     |            |     |            |     |            |   |
| Depreciation of property, plant and equipment                                                  |     |      |     |            |     |            |     |            |   |
| - Research and development costs                                                               |     |    9 |     |        135 |     |        162 |     |        198 |   |
| - Administrative costs                                                                         |     |    9 |     |          8 |     |         12 |     |         15 |   |
| Depreciation of right of use asset                                                             |     |      |     |            |     |            |     |            |   |
| - Research and development costs                                                               |     |    9 |     |        113 |     |        151 |     |        165 |   |
| - Administrative costs                                                                         |     |    9 |     |         24 |     |         15 |     |         25 |   |
| Amortisation of intangible assets – software                                                   |     |      |     |            |     |            |     |            |   |
| - Research and development costs                                                               |     |   11 |     |          3 |     |          3 |     |          – |   |
| Impairment of financial asset(1)                                                               |     |   13 |     |         79 |     |        207 |     |          – |   |
| Provision against future loss on loan agreement                                                |     |   17 |     |          – |     |        207 |     |          – |   |
| Fees payable to the Company’s auditor for the audit of the parent Company financial statements |     |